FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ruchefsky Steven B 		2. Issuer Name and Ticker or Trading Symbol

Arno Therapeutics, Inc [ ARNI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

200 ROUTE 31 NORTH, SUITE 104 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/28/2014
(Street)

FLEMINGTON, NJ 08822
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  1596272   I   By Commercial Street Capital, LLC   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $8.00                      (2) 11/5/2020   Common Stock   3750     3750   D  
 
Stock Option (right to buy)   $2.40                      (3) 11/4/2023   Common Stock   205344     205344   D  
 
Stock Option (right to buy)   $2.90                      (4) 1/24/2024   Common Stock   34224     34224   D  
 
Stock Option (right to buy)   $.85   11/4/2014     A      136784         (5) 11/4/2024   Common Stock   136784   $0   136784   D  
 
Warrants (right to buy)   $8.80                    9/9/2010   9/9/2015   Common Stock   3125     3125   D  
 
2010 Class B Warrants (right to buy)   $3.08                    10/29/2013   9/9/2015   Common Stock   115500     115500   I   By Commercial Street Capital, LLC   (1)
2012 Series A Warrants (right to buy)   $2.40                    10/29/2013   11/26/2017   Common Stock   868055     868055   I   By Commercial Street Capital, LLC   (1)
2012 Series B Warrants (right to buy)   $2.40   10/28/2014     D   (6)       520833    10/29/2013   10/31/2014   Common Stock   520833   $0   0   I   By Commercial Street Capital, LLC   (1)
2012 Series B Warrants (right to buy)   $2.40   10/28/2014     A   (6)    520833       10/29/2013   12/31/2014   Common Stock   520833   $0   520833   I   By Commercial Street Capital, LLC   (1)
2013 Series D Warrants (right to buy)   $4.00                    10/29/2013   10/29/2018   Common Stock   687500     687500   I   By Commercial Street Capital, LLC   (1)
2013 Series E Warrants (right to buy)   $2.40   10/28/2014     D   (6)       687500    10/29/2013   10/31/2014   Common Stock   687500   $0   0   I   By Commercial Street Capital, LLC   (1)
2013 Series E Warrants (right to buy)   $2.40   10/28/2014     A   (6)    687500       10/29/2013   12/31/2014   Common Stock   687500   $0   687500   I   By Commercial Street Capital, LLC   (1)

Explanation of Responses:
( 1)  The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
( 2)  Vests in three equal annual installments commencing 11/5/11.
( 3)  Vests in equal 36-monthly installments commencing 12/4/13.
( 4)  Vests in equal 12-monthly installments commencing 2/24/14.
( 5)  Vests in equal 36-monthly installments commencing 12/4/14.
( 6)  The two reported transactions resulted from the Issuer's unilateral extension of the expiration date of two outstanding warrants from 10/31/14 to 12/31/14. Such extension resulted in the deemed cancellation of the "originally" issued old warrant and the issuance of a replacement warrant. The Series B warrant was originally granted on 11/26/12 and the Series E warrant was originally granted on 10/29/13.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ruchefsky Steven B
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON, NJ 08822 		X



Signatures
/s/ Christopher J. Melsha as Attorney-in-Fact for Steven B. Ruchefsky pursuant to Power of Attorney previously filed 11/6/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Arno Therapeutics (CE) Charts.
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Arno Therapeutics (CE) Charts.